essent-tarra-2

Providing Researchers with the Gold Standard in Tissue Engineering

Centennial, Colo. — January  24, 2023 — Essent Biologics™, a leading supplier of human-derived cell and scaffold materials, today announced availability of its Human Native Tissue-Derived Type I Atelocollagen for the cell and tissue engineering industry.  Extracted and purified from human tissue, Essent’s Human Native Tissue-Derived Type I Atelocollagen contains comprehensive properties—making it the first choice for two- and three-dimensional cell culture, labware coating applications, drug delivery, bioprinting, and as a scaffold for a myriad tissue engineering modalities.

As the main structural protein in the human body, native Type I collagen is crucial to a vast array of medical and scientific research, providing structure to 3D scaffolds and an ideal ex-vivo environment for the attachment, proliferation, differentiation, and migration of cells. Essent’s Human Native Tissue-Derived Type I Atelocollagen is isolated from the skin of consenting tissue donors aged 18-30 years old, processed under antibiotic-free conditions and evaluated for purity, identity, functionality, sterility, and endotoxin.

“We are thrilled to launch our Human Native Tissue-Derived Atelocollagen to the market,” said Corey Stone, President of Essent Biologics. “With a purity ranging from 95-100%, our collagen is poised to provide one of the highest standards in quality—allowing our customers to have a better and more consistent starting material in their research and manufacturing.”

Essent’s Human Native Tissue-Derived Type I Atelocollagen is optimal for many cell and tissue engineering applications because it has undergone the natural extracellular post-translational modifications and interacted with other biomolecules from the matrisome.

For additional information on the company’s product pipeline, please visit essentbiologics.org/products/.

Centennial, Colo. — December 13, 2022 — Essent BiologicsTM, a leading supplier of human-derived cell and scaffold materials, today announced availability of its Micronized Bone Matrix (MBM) for 3D bioprinting and tissue engineering applications. Essent Biologics will provide a mineralized allograft bone matrix derived from human ground cortical bone that contains native proteins, such as Collagen Type I, and native elements and minerals, such as calcium and phosphorus.

With the increased focus on additive manufacturing technologies to advance bone tissue engineering, the demand for biologically relevant scaffolds and bio-ink additives has grown at a steady pace. As an integral part of bone tissue engineering, scaffolds are 3D biocompatible structures which can mimic the ECM properties—including mechanical support and cellular stimulation through biochemical and mechanical interactions—and provide a template for cell attachment to stimulate bone tissue formation.

“Providing this human scaffolding material provides a ready-made, biologically relevant bioink additive for researchers in the 3D Printing world,” said Jeffrey Brown, Executive Vice President of Research & Development at Essent Biologics. “Essent’s MBM, along with our previously launched demineralized ground bone product, Spectral DBM, will support the work of those interested in human bone characterization as well as the burgeoning field of bone tissue engineering.”

Essent Biologics’ MBM is provided at a compatible size for extrusion 3D bioprinting, with a ≤300μm particle size, and is recovered and processed without the use of animal products.

For additional information on the company’s product pipeline, please visit essentbiologics.org/products/.

Providing Researchers with Breakthrough Materials to Investigate Pre-Eclampsia

Centennial, Colo. — August 23, 2022 — Essent Biologics™, a leading supplier of human-derived cell and scaffold materials, today announced availability for investigational researchers to obtain human pre-eclamptic cytotrophoblasts and Hofbauer cells through its distribution agreement with the Amnion Foundation.

The Amnion Foundation successfully isolated cytotrophoblasts and Hofbauer cells from the post-partum placenta of a donor with confirmed pre-eclampsia, enabling researchers to further investigate disease mechanisms at the cellular level and identify key differences in health and disease.
Pre-eclampsia is one of the leading causes of death in pregnant women, yet treatment options are limited and the disease etiology is poorly understood. Research studies are crucial to elucidating mechanisms and developing new effective treatments that improve the lives of both mother and child.
“The Amnion Foundation team leveraged their proprietary methods to establish disease-origin cytotrophoblasts and Hofbauer cells from a pre-eclamptic placenta,” said Sharon Presnell, Ph.D., President and Director of Client Services for Amnion Foundation. “This provides an exciting opportunity for researchers in this space to expand their efforts and investigate cellular function in both health and disease using well characterized cells. Together, with Essent, we have reached an important milestone on our mission to make living cells from birth tissue accessible to support the development of life-changing therapies.”

“We are proud to have a collaborative relationship with such an innovative partner in the Amnion Foundation,” said Dr. Jeff Brown. “It’s exciting to be able to support the Amnion Foundation with this breakthrough in post-partum research tools. The availability of these rare cells will open up new avenues for researchers and clinicians to further investigate this complicated disorder that affects so many mothers and babies.”